Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil
Abstract
Authors
A.M. Nishikawa L. Paladini A.L. Liamas C.C. Bueno O.A.C. Clark